Donate For Public and Patients Store Search

S043 - Acne and Rosacea

Sunday, March 3; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Select the best treatment for patients with acne and rosacea
  • Differentiate types of rosacea to utilize appropriate treatment options
  • Describe new developments in the pathogenesis of acne

Description

This session will provide an overview on new development in the pathogenesis of acne. It will provide the audience with evidenced based data on efficacy of new treatment options for acne and rosacea. Leading experts will offer their best practices for complicated patients.

Disclosures

  • Baldwin, Hilary E., MD: Allergan, Inc. – A(H); Bayer – SP(NC); Dermira – I(Grants/Research Funding); Galderma Laboratories, L.P. – SP(H); Novan – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – SP(H); Valeant Pharmaceuticals International – SP(H);
  • Del Rosso, James Q., DO: AbbVie – I(Grants/Research Funding); Aclaris Therapeutics Inc. – C(H), I(Grants/Research Funding), SP(H); Almirall – C(H); AnaptysBio – I(Grants/Research Funding); Athenix – I(Grants/Research Funding); BioPharmX – I(Grants/Research Funding); Botanix Pharmaceuticals – I(Grants/Research Funding); Cassiopea S.p.A. – C(H); Celgene Corporation – C(H), I(Grants/Research Funding), SP(H); Cutanea Life Sciences – A(H), I(Grants/Research Funding), SP(H); Dermavant Sciences – A(H); Dermira – C(H), I(Grants/Research Funding), SP(H); Encore Dermatology, Inc. – C(H), SP(H); Ferndale Laboratories, Inc. – C(H); Foamix – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – SP(H); L'Oreal USA Inc. – A(H); La Roche-Posay Laboratorie Pharmaceutique – C(H); Leo Pharma Inc. – C(H), I(Grants/Research Funding); LEO Pharma, US – SP(H); Mayne Pharma Group – A(H), SP(H); Menlo Therapeutics – A(H), I(Grants/Research Funding); Novan – C(H), I(Grants/Research Funding); Ortho Dermatologics – C(H), I(Grants/Research Funding); Othro Dermatologics – SP(H); Pfizer Inc. – A(H), SP(H); Promius Pharma, LLC – I(Grants/Research Funding); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – E(S), SP(H); Sanofi Genzyme – SP(H); Sebacia, Inc. – C(H), I(Grants/Research Funding); Skinfix, Inc. – C(H); Sol-Gel Technologies – C(H), I(Grants/Research Funding); Sonoma Pharmaceuticals – C(H); Sun Pharmaceutical Industries Ltd. – C(H), I(Grants/Research Funding), SP(H); Unilever Home & Personal Care USA – A(H); Verrica Pharmaceuticals Inc – C(H);
  • Desai, Seemal R., MD: AbbVie – I(Grants/Research Funding); Almirall – C(Fees), SP(H); Cassiopea SpA – C(H); Dermavant Sciences – A(Fees); Dermira – C(H), I(Grants/Research Funding), SP(H); Dr. Reddy – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – A(Fees); Galderma Laboratories, LP – C(Fees); Menlo Therapeutics – C(H), I(Grants/Research Funding); Ortho Dermatologics – C(H), SP(H); Pfizer Inc. – SP(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Scientis – C(H), SP(H); SkinCeuticals LLC – C(H);
  • Harper, Julie Claire, MD: Aclaris Therapeutics Inc. – A(H); Allergan, Inc – SP(H); Aqua – C(H); Bayer Pharmaceuticals – I(Fees), O(H); BioPharmX – A(H); Dermira – A(H); Galderma Laboratories, L.P. – C(H); Galderma USA – SP(H); La Roche-Posay Laboratoire Pharmaceutique – SP(H); Novan – A(H); Promius Pharma, LLC – SP(H); Sun Pharmaceutical Industries Ltd. – C(Fees); Taro Pharm – A(H); Valeant Pharmaceuticals North America LLC – SP(H);
  • Kim, Jenny J., MD, PhD: Almirall – C(H); Sienna Biopharmaceuticals – SH(ST); SmartPhage, Inc. – C(H);
  • Kircik, Leon H., MD: 3M Pharmaceuticals – I(Grants/Research Funding), SP(H); Abbott Laboratories – SP(H); Ablynx – I(Grants/Research Funding); Acambis – I(Grants/Research Funding); Allergan, Inc – A(H), C(H), I(H), SP(H); Almirall – C(H); Amgen – C(H), I(Grants/Research Funding), SP(H); AnaptysBio – I(Grants/Research Funding); Aqua – A(H); Astellas Pharma US, Inc – I(Grants/Research Funding), SP(H); Asubio Pharmaceuticals, Inc. – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Beiersdorf, Inc. – C(H), I(Grants/Research Funding); Biogen – A(H); Biolife – I(Grants/Research Funding); Biopelle, Inc. – I(Grants/Research Funding); Breckinridge Pharma – I(Grants/Research Funding); Cassiopea SpA – C(H); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); ColBar LifeScience Ltd. – A(H), C(H); CollaGenex Pharmaceuticals, Inc. – C(H), I(Grants/Research Funding), SP(H); Connetics Corporation – A(H), C(H), I(Grants/Research Funding); Coria Laboratories – I(Grants/Research Funding); Dermik Laboratories, a business of sanofi-aventis U.S. LLC – SP(H); Dow Pharmaceutical Sciences, Inc. – I(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – I(Grants/Research Funding); Embil Pharmaceuticals, Co., Ltd – SP(H); EOS – A(H); Ferndale Laboratories, Inc. – A(H), I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), C(H), I(Grants/Research Funding), SP(H); Genentech, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); GlaxoSmithKline – I(Grants/Research Funding); Healthpoint – I(Grants/Research Funding); Intendis, Inc. – A(H), C(H), I(Grants/Research Funding); Isdin – A(H); Johnson & Johnson Consumer Products Company – A(H), C(H), I(Grants/Research Funding), SH(ST), SP(H); Laboratory Skin Care, Inc. – C(H); Leo Pharma Inc – C(H), I(Grants/Research Funding), SP(H); Medical International Technologies – C(H); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc – C(H); Merck Serono – SP(H); Merz Pharmaceuticals, LLC – C(H); NanoBio Corporation – A(H), I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Nucryst – I(Grants/Research Funding); Obagi Medical Products – I(Grants/Research Funding); Onset Dermatologics – I(Grants/Research Funding), SP(H); Othro Dermatologics – A(H), C(H), I(Grants/Research Funding), SP(H); Pfizer Inc. – I(Grants/Research Funding); Pharmaderm – I(Grants/Research Funding), SP(H); Promius Pharma, LLC – A(H), C(H), I(Grants/Research Funding); PuraCap Pharmaceutical – C(H); QLT Inc. – I(H); SkinMedica, Inc. – A(H), C(H), I(Grants/Research Funding), SP(H); Stiefel a GSK company – A(H), C(H), I(Grants/Research Funding), SP(H); Sun Pharmaceutical Industries Ltd. – A(H), SP(H); Taro Pharm – C(H), I(Grants/Research Funding); TolerRx – I(Grants/Research Funding); Triax Pharmaceuticals, LLC – C(H), I(Grants/Research Funding), SP(H); Valeant Pharmaceuticals International – A(H), C(H), I(Grants/Research Funding), SP(H); Warner Chilcott – A(H), I(Grants/Research Funding), SP(H); Xenoport, Inc. – I(Grants/Research Funding); Zalicus – I(Grants/Research Funding);
  • Leyden, James Joseph, MD: Avon Products, Inc. – C(H); BioPharmX – C(H); Cutanea Life Sciences – C(H); Galderma Laboratories, L.P. – C(H); Photosonix – C(H); Sol-Gel Technologies – C(H); Unilever Home & Personal Care USA – C(H);
  • Ozog, David M., MD: Biofrontera AG – I(Grants/Research Funding), SH(NC); Galderma USA – I(Grants/Research Funding); miRagen Therapeutics, Inc. – I(Grants/Research Funding);
  • Stein Gold, Linda F., MD: AbbVie – A(H); Actavis – SP(H); Allergan, Inc. – I(Grants/Research Funding); Aqua – A(H); Botanix Pharmaceuticals – C(H); Dermavant Sciences – A(H); Dermira – SP(H); Foamix – A(H); Galderma Laboratories, L.P. – A(H), I(Grants/Research Funding); La Roche-Posay Laboratorie Pharmaceutique – A(H); Leo Pharma Inc. – I(Grants/Research Funding); LEO Pharma, US – A(H); Lilly ICOS LLC – A(H); Merz Pharmaceuticals, LLC – A(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Pfizer Inc. – A(H), I(Grants/Research Funding); Promius Pharmaceuticals – A(H); Roche Laboratories – Independent Contractor(Fees), O(H); Sol-Gel Technologies – C(Grants/Research Funding); Taro Pharm – A(H), C(H); Topica – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(H), I(Grants/Research Funding);
  • Thiboutot, Diane M., MD: Cassiopea SpA – C(Fees); Dermira – A(Fees); Galderma Laboratories, L.P. – A(H); Novan – C(Fees); Novartis – C(Fees); Sebcaia, Inc – C(H);
  • Webster, Guy F., MD, PhD: AbbVie – A(Fees); Aclaris Therapeutics Inc. – C(Fees); Allergan, Inc. – A(Fees); Anterios Inc. – C(Fees); BioPharmX – C(H); Cutanea Life Sciences – C(Fees); Dermira – C(Fees), SH(ST); Foamix – C(Fees); Galderma Laboratories, L.P. – C(Fees); Janssen Pharmaceuticals, Inc – C(Fees); OPKO Health, Inc – SH(NC); Ralexar Therapeutics, Inc – C(Fees); Ranbaxy Laboratories Limited – C(Fees); Sienna Biopharmaceuticals – SH(ST); Sol-Gel Technologies – C(Fees); Valeant Pharmaceuticals International – C(Fees);
Schedule
Sunday, March 3
1:00 PM
Dr. Kim / What's New in the pathogenesis of acne
1:15 PM
Dr. Kircik / Clinical trial: Interpreting the data
1:23 PM
Dr. Stein Gold / Acne: What's New and What's on the Horizon
1:38 PM
Dr. Harper / Acne in Women
1:53 PM
Dr. Thiboutot / Isotretinoin: Special Considerations
2:08 PM
Dr. Stein Gold, Dr. Thiboutot, Dr. Kircik, and Dr. Harper / Q and A
2:20 PM
Dr. Baldwin / Rosacea: What's New
2:35 PM
Dr. Del Rosso / Antibiotics: Important considerations
2:50 PM
Dr. Desai / Treating patients with skin of color
3:05 PM
Dr. Webster / Acne: Challenging cases
3:15 PM
Dr. Ozog / Treating acne scars
3:30 PM
Dr. Leyden / Important lessions I've learned over a career in acne and rosacea
3:45 PM
All faculty / Q and A
Event Details
  • Date
    Sunday, March 3
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 207A
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Linda F. Stein Gold, MD, FAAD
Speakers
  • David M. Ozog, MD, FAAD
  • Diane M. Thiboutot, MD
  • Guy F. Webster, MD, PhD, FAAD
  • Hilary E. Baldwin, MD, FAAD
  • James Joseph Leyden, MD, FAAD
  • James Q. Del Rosso, DO, FAAD
  • Jenny J. Kim, MD, PhD, FAAD
  • Julie Claire Harper, MD, FAAD - Handout
  • Leon H. Kircik, MD, FAAD
  • Seemal R. Desai, MD, FAAD